




ONCE-DAILY  
**INGREZZA**<sup>®</sup>  
(valbenazine) capsules

FOR ADULTS WITH TARDIVE DYSKINESIA (TD)

**Only INGREZZA offers a therapeutic dose from Day 1<sup>1</sup>**

**START AT**

**40** mg



Capsules not actual size

**ADJUST IF NEEDED**

**60** mg



**80** mg



Adjust after 1 week based on response and tolerability.  
Recommended dose is 80 mg.



**All doses available in capsules and sprinkle formulation**

#### **Important Information** **INDICATION & USAGE**

INGREZZA<sup>®</sup> (valbenazine) capsules and INGREZZA<sup>®</sup> SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease.

#### **IMPORTANT SAFETY INFORMATION**

**Depression and Suicidality in Patients with Huntington's Disease:** VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington's disease.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed Warning.



**FACILITY FRIENDLY DOSING<sup>1</sup>**

No titration required  
Capsule or sprinkle



## No other VMAT2 inhibitor can offer the simplicity of INGREZZA<sup>1</sup>

### WHY WAIT?



Therapeutic dose from Day 1

### WHY TITRATE?




No required titration

### WHY OVERCOMPLICATE?



Start with INGREZZA

## WHY WAIT UNTIL DAY 28? | WITH DEUTETRABENAZINE?<sup>3</sup>



**Most patients** (52%) were between **36 and 48 mg/day** and even 3% were >48 mg/day at the end of long-term study<sup>4</sup>



### WHY TITRATE?

Re-titration required for deutetrabenazine following discontinuation or interruption of treatment  $\geq 1$  week<sup>3</sup>

Dosing comparison does not imply superiority of efficacy or safety.

For complete dosing information, please refer to each product's Prescribing Information.

## IMPORTANT SAFETY INFORMATION (continued)

### CONTRAINDICATIONS

INGREZZA and INGREZZA SPRINKLE are contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE.

### WARNINGS & PRECAUTIONS

#### Hypersensitivity Reactions

Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in patients after taking the first or subsequent doses of INGREZZA. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA or INGREZZA SPRINKLE.

#### Somnolence and Sedation

INGREZZA and INGREZZA SPRINKLE can cause somnolence and sedation. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA or INGREZZA SPRINKLE.

#### QT Prolongation

INGREZZA and INGREZZA SPRINKLE may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA and INGREZZA SPRINKLE should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

#### Neuroleptic Malignant Syndrome

A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission, including INGREZZA. The management of NMS should include immediate discontinuation of INGREZZA or INGREZZA SPRINKLE, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems. If treatment with INGREZZA or INGREZZA SPRINKLE is needed after recovery from NMS, patients should be monitored for signs of recurrence.


#### Parkinsonism

INGREZZA and INGREZZA SPRINKLE may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA or INGREZZA SPRINKLE treatment in patients who develop clinically significant parkinson-like signs or symptoms.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed Warning.

## ONLY INGREZZA offers a sprinkle formulation to treat TD<sup>1</sup>

For residents who cannot or choose not to take a pill



Can be sprinkled over soft food

Do not crush or chew INGREZZA SPRINKLE (valbenazine), and do not administer via nasogastric, gastrostomy, or other enteral tubes as it may cause obstruction.

**DEUTETRABENAZINE XR/BID is on the DO NOT CRUSH LIST<sup>5</sup>**

### IMPORTANT SAFETY INFORMATION (continued)

#### ADVERSE REACTIONS

The most common adverse reaction in patients with tardive dyskinesia (≥5% and twice the rate of placebo) is somnolence.

The most common adverse reactions in patients with chorea associated with Huntington's disease (≥5% and twice the rate of placebo) are somnolence/lethargy/sedation, urticaria, rash, and insomnia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

**Dosage Forms and Strengths:** INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.

Please see accompanying full Prescribing Information, including Boxed Warning.

**REFERENCES:** 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc. 2. Data on file as of Q3 2024. Neurocrine Biosciences, Inc. 3. Deutetrabenazine [package insert]. Parsippany, NJ: Teva Neuroscience, Inc. 4. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. *Front Neurol.* 2022;13:773995. 5. PharMerica. Oral Medications That Should Not Be Crushed or Altered. October 2024. Accessed May 1, 2025. [https://pharmerica.com/wp-content/uploads/2024/10/PMC-DKY-Do-Not-Crush-List-100324\\_FINAL.pdf](https://pharmerica.com/wp-content/uploads/2024/10/PMC-DKY-Do-Not-Crush-List-100324_FINAL.pdf).


# TD HCP LTC DOSING CARD 2025 SCHEMATIC

Front cover-folded


Back cover-folded with pocket on top

Inside spread-open

Cover, 9" x 9"



Inside spread, 9" x 18"



Back, 9" x 9"

